ChemicalBook >> CAS DataBase List >>Vorinostat

Vorinostat

CAS No.
149647-78-9
Chemical Name:
Vorinostat
Synonyms
Suberoylanilide hydroxamic acid;N1-hydroxy-N8-phenyloctanediaMide;SAHA cpd;Vornostat;vorinosta;Vorinostat (SAHA, MK0683);suberoylaMide hydroxaMic acid;MK0683;CS-1949;FuLi, he
CBNumber:
CB3506806
Molecular Formula:
C14H20N2O3
Molecular Weight:
264.32
MDL Number:
MFCD00945317
MOL File:
149647-78-9.mol
MSDS File:
SDS
Last updated:2023-12-18 16:59:08

Vorinostat Properties

Melting point 161-162°C
Density 1.2
RTECS RG8835000
storage temp. -20°C
solubility DMSO: ≥15mg/mL
form powder
pka 9.48±0.20(Predicted)
color white to tan
Merck 14,10034
Stability Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 6 months.
InChIKey WAEXFXRVDQXREF-UHFFFAOYSA-N
CAS DataBase Reference 149647-78-9(CAS DataBase Reference)
NCI Dictionary of Cancer Terms suberoylanilide hydroxamic acid; vorinostat
FDA UNII 58IFB293JI
NCI Drug Dictionary vorinostat
ATC code L01XH01

SAFETY

Risk and Safety Statements

Symbol(GHS)  GHS hazard pictograms
GHS08
Signal word  Danger
Hazard statements  H341-H360
Precautionary statements  P201-P308+P313
Hazard Codes  T
Risk Statements  61-68
Safety Statements  53-36/37-45
WGK Germany  3
HS Code  29280000
NFPA 704
0
2 0

Vorinostat price More Price(54)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich SML0061 SAHA ≥98% (HPLC) 149647-78-9 5mg $95.3 2024-03-01 Buy
Sigma-Aldrich SML0061 SAHA ≥98% (HPLC) 149647-78-9 25mg $388 2024-03-01 Buy
TCI Chemical H1388 N-Hydroxy-N'-phenyloctanediamide >98.0%(HPLC)(N) 149647-78-9 200mg $318 2024-03-01 Buy
Alfa Aesar H37305 Vorinostat 98% 149647-78-9 250mg $117 2021-12-16 Buy
Alfa Aesar H37305 Vorinostat 98% 149647-78-9 1g $269 2021-12-16 Buy
Product number Packaging Price Buy
SML0061 5mg $95.3 Buy
SML0061 25mg $388 Buy
H1388 200mg $318 Buy
H37305 250mg $117 Buy
H37305 1g $269 Buy

Vorinostat Chemical Properties,Uses,Production

Antitumor drugs

Vorinostat is a novel, molecularly targeted antineoplastic agent that causes cell cycle arrest and/or apoptosis by inhibiting histone deacetylase (HDAC). It is the first HDAC inhibitor approved by the US Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma (CTCL) with significant skin involvement that is still progressing, resistant or relapsing after two systemic regimens.
On October 6, 2006, the US Food and Drug Administration (FDA) have approved vorinostat capsules (vorinostat) for the treatment of skin cancer drugs. The drug is the first novel type of anti-cancer drugs of histone deacetylase inhibitor developed by the United States Merck for the treatment of skin T cell lymphoma (CTCL). FDA has approved it for the treatment of metastatic skin T-cell lymphoma which is unable to be cured or even worsened or gets recurrent cases. A large number of experimental studies and clinical results have shown that vorinostat has a excellent efficacy on a variety of tumors and have significant synergies when combined with other oncology drugs. The current treatment of other tumors is still undergoing in-depth study; these results show that vorinostat has a broad market prospects.
Vorinostat has low toxicity with the evidence of its safety and efficacy being supported by two clinical trials, including 107 patients with CTCL who had gotten relapsed after receiving other drugs. According to the standard analysis of improvement in the grade of skin lesion, 30% of patients treated with Zolinza get symptoms improved, with the average efficacy duration of 168 days. The most common serious adverse events were pulmonary embolism, dehydration, deep venous thrombosis and anemia. Common adverse reactions are gastrointestinal symptoms (including diarrhea, nausea and loss of appetite, vomiting and constipation); fatigue, chills and taste disorders. Animal experiments showed that pregnant women should be banned of using the drug.

Preparation

Suberic acid can undergo the intramolecular dehydration into suberic anhydride under the action of the acetic anhydride. The suberic anhydride, together with aniline can have ring-opening amidation in ethyl acetate at 0 °C to generate suberic acid monoanilide, followed by methanol esterification and hydroxylamine amine aminolysis to obtain the anti-tumor drug in vorinostat with the total yield of about 65%.
"Chinese Journal of Pharmaceutical Industry" 2009, Volume 40, No. 7, pages 481-483

Anti-cancer drug Vorinostat was able to clear latent HIV virus

Researchers from the University of North Carolina at Chapel Hill have published a groundbreaking research paper in the July 25, 2012 issue of Nature to confirm that a deacetylase inhibitor drug – vorinostat that can be used to treat certain types of lymphoma-being capable of clearing out the patient's latent HIV virus in vivo.
The researchers have conducted a series of experiments to evaluate the potential of this drug to activate and destroy latent HIV viruses. Initially, laboratory experiments for measuring the level of active HIV in CD4 + T cells showed that vorinostat can take off the camouflage of latent HIV viruses in these cells. Then, eight male patients who still kept medically stable HIV infection after antiretroviral therapy, took vorinostat, and then were tested their active HIV levels in the body and compared it to the levels they had before taking the drug.
The researchers found that HIV-RNA levels in CD4 + T cells increased by an average of 4.5-fold in those patients who receiving vorinostat, confirming that the HIV virus was disguised. This is the first published study confirming that deacetylase inhibitors have the potential to break down latency in latent virus libraries. The study provides convincing evidence that a new strategy may be used to directly attack and eradicate latent HIV infection. However, getting rid of the latent nature of HIV is only the first step in curing HIV infection.

Description

Vorinostat is the first drug in a new class of anti-cancer agents that inhibit histone deacetylases (HDAC). It was launched as an oral treatment for cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent, or recurrent disease on or following two systemic therapies. HDACs are enzymes that catalyze the removal of the acetyl modification on lysine residues of proteins, including the core nucleosomal histones. Together with their counterpart histone acetyltransferases (HATs), HDACs regulate the acetylation level of the histones, which plays an important role in the regulation of chromatin plasticity and gene transcription. Hypoacetylation of histones is associated with a condensed chromatin structure resulting in the repression of gene transcription, whereas acetylated histones are associated with a more open chromatin structure and activation of transcription. In some cancer cells, there is an overexpression of HDACs, resulting in hypoacetylation of histones. Inhibitors of HDAC are thought to transcriptionally reactivate dormant tumor-suppressor genes by allowing for the accumulation of acetyl groups on histones and an open chromatin structure. Vorinostat inhibits the enzymatic activity of HDAC1, HDAC2, HDAC3, and HDAC6 at nanomolar concentrations (IC50 <86 nM). In vitro, it induces growth arrest, differentiation or apoptosis in a variety of tumor cells. In addition, vorinostat inhibits tumor growth in animal models bearing solid tumors, including breast, prostate, lung and gastric cancers, as well as hematologic malignancies such as multiple myeloma and leukemias.

Chemical Properties

White Crystalline Solid

Originator

Columbia University (US)

Uses

A potent HDAC inhibitor; also causes cell cycle arrest at G1

Uses

antineoplastic, histone deacetylase inhibitor

Uses

A potent, selective, cell permeable histone deacetylase inhibitor (HDAC). Displays anti-angiogenic activity by interfering with VEGF signaling in human umbilical vein endothelial cells (HUVECs). Induces differentiation in uman breast cancer cells.

Uses

Vorinostat, a histone deacetylase (HDAC) inhibitor from Merck, was approved for the treatment of cutaneous T-cell lymphoma (CTCL), a type of non-Hodgkin’s lymphoma. Vorinostat was shown to inhibit HDAC1, HDAC2, HDAC3 and HDAC6 at nanomolar concentrations. HDAC inhibitors are potent differentiating agents toward a variety of neoplasms, including leukemia and breast and prostate cancers.

Uses

Suberoylanilide Hydroxamic Acid is a potent, selective, cell permeable histone deacetylase inhibitor (HDAC). Suberoylanilide Hydroxamic Acid displays anti-angiogenic activity by interfering with VEGF signaling in human umbilical vein endothelial cells (HUVECs). Suberoylanilide Hydroxamic Acid induces differentiation in uman breast cancer cells.

Definition

ChEBI: A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

brand name

Zolinza

General Description

Histones are proteins around which DNA is wound in the process of packing DNA into the nucleus. They also havea role in regulating the transcription of genes, and this iscontrolled by the covalent modifications acetylation, phosphorylation,and methylation to which they are subject.
Vorinostat fits the basic pharmacophore for the HDACis, which consists of a hydrophobic cap regionconnected to a zinc coordinating functionality by a hydrophobiclinker.The hydroxamic acid functionality iscapable of bidendate binding to zinc present in the enzymeand is a major factor in the overall binding of the compound.The compound inhibits HDAC1, 2, 3, and 6 classes of thisenzyme with nanomolar (<86 nM) IC50 values.
The agent is given orally and is available in 100-mg capsulesfor the treatment of cutaneous T-cell lymphoma. Thebioavailability is 43%, and the agent is 71% bound toplasma proteins. Extensive metabolism of the agent occursto give the O-glucuronide of the hydroxamic acid functionand 4-anilino-4-oxobutanoic acid with minimal involvementof isozymes of CYP. The metabolites, both of whichare inactive, are eliminated in the urine and the drug has aterminal elimination half-life of 2 hours. The most commonlyreported adverse effects are fatigue, diarrhea, andnausea.

Biochem/physiol Actions

SAHA or Vorinostat facilitates the transcription of genes that result in apoptosis, differentiation and growth arrest. It has been observed to give beneficial results in lymphoma but not in solid tumors.

Synthesis

Commercially available monomethyl ester 125 was reacted with aniline in the presence of DCC and HOBt in DMF to give amide 127 in 89% yield.

Synthesis_149647-78-9

Methyl ester amide 127 was then reacted with hydroxylamine HCl salt and potassium hydroxide in methanol to give vorinostat (XVI) in 90% yield.

storage

-20°C

References

1) Vrana et al. (1999), Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun and p21CIP1, but independent of p53; Oncogene, 18 7016 2) Butler et al. (2002), The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin; Proc. Natl. Acad. Sci. USA, 99 11700 3) Tang et al. (2012), Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells, 13 567

Vorinostat Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 430)Suppliers
Supplier Tel Email Country ProdList Advantage
Shanghai Chinqesen Biotechnology Co., Ltd.
+86-16628886292 +86-19521323435 sales2@qschem-pharma.com China 253 58
Hebei Mojin Biotechnology Co., Ltd
+8613288715578 sales@hbmojin.com China 12452 58
Hebei Lingding Biotechnology Co., Ltd.
+86-18031140164 +86-19933155420 erin@hbldbiotech.com China 882 58
Henan Bao Enluo International TradeCo.,LTD
+86-17331933971 +86-17331933971 deasea125996@gmail.com China 2504 58
Shaanxi Haibo Biotechnology Co., Ltd
+86-02963020060 +86-18629295024 hibo06@xaltbio.com China 1000 58
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512 info@tianfuchem.com China 21700 55
Nanjing ChemLin Chemical Industry Co., Ltd.
025-83697070 product@chemlin.com.cn CHINA 3012 60
Nanjing Finetech Chemical Co., Ltd.
025-85710122 17714198479 sales@fine-chemtech.com CHINA 885 55
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795 ivan@atkchemical.com China 32480 60
career henan chemical co
+86-0371-86658258 sales@coreychem.com China 29914 58

View Lastest Price from Vorinostat manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Vorinostat pictures 2024-01-20 Vorinostat
149647-78-9
US $9.90-9.90 / g 5g 99.99%HPLC.USP42——Powder、Oil、Pills、Capsules、Tablets,Customiz 100kg Wuhan Biocar Pharmacy Co., Ltd.
Vorinostat pictures 2023-12-18 Vorinostat
149647-78-9
US $0.00-0.00 / kg 1kg 0.99 50000kg Hebei Yibangte Import and Export Co. , Ltd.
Vorinostat pictures 2023-12-11 Vorinostat
149647-78-9
US $30.00-20.00 / kg 1kg 99% 2000000 Shanghai Chinqesen Biotechnology Co., Ltd.
  • Vorinostat pictures
  • Vorinostat
    149647-78-9
  • US $9.90-9.90 / g
  • 99.99%HPLC.USP42——Powder、Oil、Pills、Capsules、Tablets,Customiz
  • Wuhan Biocar Pharmacy Co., Ltd.
  • Vorinostat pictures
  • Vorinostat
    149647-78-9
  • US $0.00-0.00 / kg
  • 0.99
  • Hebei Yibangte Import and Export Co. , Ltd.
  • Vorinostat pictures
  • Vorinostat
    149647-78-9
  • US $30.00-20.00 / kg
  • 99%
  • Shanghai Chinqesen Biotechnology Co., Ltd.
UNII-58IFB293JI Octanediamide, N1-hydroxy-N8-phenyl- SAHA=N-Hydroxy-N'-phenyloctanediamide SAHA, N-Hydroxy-Nphenyloctanediamide, Zolinza Zolinza (See Suberoylanilide Hydroxamic Acid) Vorinostat N-Hyrdroxy-N'-phenyloctanediamide Vorinostat for research Zolinza (See S688700) Vorinostat/SAHA suberoylanilide hydroxaMic acid suberanilohydroxaMic acid Suberanilohydroxamic acid MK0683 Vorinostat-13C6 VoriNAstat Vorinostat Impurity SAHA, >=99% CCRIS 8456 Octanediamide,N-hydroxy-N'-phenyl- (9CI) CS-1949 orinostat (Vorinostat) Zolinza N-Hydroxy-N'-phenyloctanediamide> Vorinostat USP/EP/BP VorinostatQ: What is Vorinostat Q: What is the CAS Number of Vorinostat Q: What is the storage condition of Vorinostat Q: What are the applications of Vorinostat SAHA (vorinostate) SAHA cpd Vornostat N1-hydroxy-N8-phenyloctanediaMide Suberoylanilide hydroxamic acid Vorinostat (SAHA, MK0683) suberoylaMide hydroxaMic acid vorinosta FuLi, he Benzeneethanamine,10-chloro-α-methyl- Vorinostat, SAHA, suberoylanilide hydroxamic acid Lithium chloride 7447-41-8 8-oxo-8-(phenylamino)octan-1-hydroxamic acid Volinotha 149647-78-9 49647-78-9 Anti-cancer & immunity ZOLINZA Inhibitor API Aromatics Inhibitors Intermediates & Fine Chemicals Pharmaceuticals 149647-78-9